Biomarker-based patient stratification utilizes genetic and protein markers, such as PI3K and AKT mutations, elevated phosphorylated protein levels, and cancer stem cell markers, to identify individuals most likely to respond to specific therapies. The gene discussed is AKT1; the disease is cancer.